Fibronectin binding protein B compounds

• US 6,077,677 A
• Filed: 12/04/1998
• Issued: 06/20/2000
• Est. Priority Date: 10/16/1995
• Status: Expired due to Fees

• Current Assignee: Smithkline Beecham PLC (GSK plc)
• Original Assignee: Smithkline Beecham PLC (GSK plc)
• Inventors: Hodgson, John Edward, Burnham, Martin Karl Russell
• Primary Examiner(s): Hutzell, Paula K.
• Assistant Examiner(s): DAVIS, MINH TAM B
• Application Number:
  US09/205,049
• Time in Patent Office: 564 Days
• Field of Search: 530/350, 536/23.1, 435/7.1, 424/234.1
• US Class Current: 435/7.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C07K 14/31 from Staphylococcus (G)
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

Novel fibronectin binding protein B polypeptides and DNA (RNA) encoding such novel fibronectin binding protein B and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such novel fibronectin binding protein B for the treatment of infection, particularly bacterial infections. Antagonists against such novel fibronectin binding protein B and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of novel fibronectin binding protein B nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding novel fibronectin binding protein B family and for detecting the polypeptide in a host.

Claims

1. An isolated protein comprising a polypeptide comprising SEQ ID NO:

1.

2. A composition comprising the isolated protein of claim 1 and a pharmaceutically acceptable carrier.

3. An isolated fusion protein comprising a heterologous amino acid sequence fused to the polypeptide of claim 1.

4. A composition comprising the isolated fusion protein of claim 3 and a pharmaceutically acceptable carrier.

5. The isolated protein of claim 1, wherein the isolated protein consists of the amino acid sequence set forth in SEQ ID NO:

1.

6. A composition comprising the isolated protein of claim 5 and a pharmaceutically acceptable carrier.

13. A method for producing antibodies in a mammal comprising:

delivering to a tissue of the mammal the isolated protein of claim 1, wherein the protein is effective to induce an immunological response to the amino acid sequence set forth in SEQ ID NO;

1; and

, wherein the polypeptide induces an immunological response to produce antibodies to the amino acid sequence set forth in SEQ ID NO;

1.

7. An isolated protein comprising a polypeptide, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of:

(a) SEQ ID NO;

1; and

,

(b) an amino acid sequence identical to SEQ ID NO;

1 except that, over the entire length corresponding to SEQ ID NO;

1, the amino acid sequence has a substitution, deletion or insertion of one amino acid.

8. A composition comprising the isolated protein of claim 7 and a pharmaceutically acceptable carrier.

9. An isolated fusion protein comprising a heterologous amino acid sequence fused to the polypeptide of claim 7.

10. A composition comprising the isolated fusion protein of claim 9 and a pharmaceutically acceptable carrier.

11. The isolated protein of claim 7, wherein the isolated protein consists of the polypeptide, wherein the polypeptide consists of the amino acid sequence selected from the group consisting of:

(a) SEQ ID NO;

1; and

,

(b) an amino acid sequence identical to SEQ ID NO;

1 except that, over the entire length corresponding to SEQ ID NO;

1, the amino acid sequence has a substitution, deletion or insertion of one amino acid.

12. A composition comprising the isolated protein of claim 11 and a pharmaceutically acceptable carrier.